Sort
17,288 grants matching “multiple sclerosis”
Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008
$397,306Richard J. Barohn · University Of Kansas Medical Center · R01 · FY2010 · FD
Role of regulatory CD4+CD25+ T cells in diabetes
$397,277Brigham And Women'S Hospital · U01 · FY2005 · DK
How do CNS fibroblasts regulate the response to neuroinflammation?
$397,238Richard Daneman · University Of California, San Diego · R01 · FY2025 · NS
MicroRNAs as T cell sensitivity Rheostats
$397,163Chang-Zheng Chen · Stanford University · R01 · FY2012 · AI
ALGORITHMS FOR FUNCTIONAL AND ANATOMICAL BRAIN ANALYSIS
$397,134Michael I Miller · Hugo W. Moser Res Inst Kennedy Krieger · P41 · FY2010 · RR
T Cell Recognition of Myelin in Multiple Sclerosis
$397,124David A. Hafler · Brigham And Women'S Hospital · R37 · FY2008 · NS
Reprogramming retinal ganglion cells for optic nerve regeneration and guidance
$397,093Xu Cao · Johns Hopkins University · R01 · FY2021 · EY
Deprescribing of Disease Modifying Agents in Older Adults with Multiple Sclerosis
$397,090Rajender R. Aparasu · University Of Houston · R01 · FY2025 · HS
Subjective Valuation of Physical Effort in Health and Disease
$396,988Vikram S Chib · Hugo W. Moser Res Inst Kennedy Krieger · R01 · FY2023 · HD
Subjective Valuation of Physical Effort in Health and Disease
$396,984Vikram S Chib · Hugo W. Moser Res Inst Kennedy Krieger · R01 · FY2022 · HD
Subjective Valuation of Physical Effort in Health and Disease
$396,978Vikram S Chib · Hugo W. Moser Res Inst Kennedy Krieger · R01 · FY2021 · HD
Low-input multiplex isolation and profiling of human immune cell subsets using an integrated microfluidics device
$396,951Nir Hacohen · Broad Institute, Inc. · U24 · FY2017 · AI
Mechanisms of E protein transcription factor-dependent iNKT cell expansion and differentiation
$396,945Barbara Lynne Kee · University Of Chicago · R01 · FY2017 · AI
Therapeutics for inflammatory bowel disease from the microbiome
$396,794Sarkis K Mazmanian · Symbiotix Biotherapies, Inc. · R41 · FY2014 · DK
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity
$396,776Deanna L Kroetz · Ohio State University · R01 · FY2023 · CA
Optic Nerve Myelination
$396,756Ben A Barres · Stanford University · R01 · FY2010 · EY
New Peptides for the Treatment of Multiple Sclerosis
$396,708Christine Beeton · Baylor College Of Medicine · R01 · FY2011 · NS
S1P Receptor Mechanisms in Neuropathic Pain
$396,661Laura J Sim-Selley · Virginia Commonwealth University · R01 · FY2015 · NS
Variation in Throughput from Single Motor Cortex Neurons to Muscles
$396,624Marc H Schieber · University Of Rochester · R01 · FY2011 · NS
Voluntary control of neuronal activity
$396,601Marc H Schieber · University Of Rochester · R01 · FY2015 · NS
3D segmentation and registration of macular SD-OCT for application in MS
$396,584Jerry L Prince · Johns Hopkins University · R01 · FY2017 · EY
Modeling and Analysis of Clinical Care for HIT Improvement
$396,579Keith Butler · University Of Washington · R01 · FY2013 · HS
Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008
$396,508Richard J. Barohn · University Of Kansas Medical Center · R01 · FY2012 · FD
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis
$396,505Richard J. Barohn · University Of Kansas Medical Center · R01 · FY2012 · FD
Mechanisms of human immune modulation by oral N-acetylglucosamine
$396,477Michael Demetriou · University Of California-Irvine · R01 · FY2015 · AT